Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 7Pancreatic Neoplasms 1Liver Neoplasms 1Digestive System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Biliary Tract Carcinoma 1Biliary Tract Adenocarcinoma 1Advanced Solid Tumor 1

Interventions

Gemcitabine 78Fluorouracil 27Oxaliplatin 24130-nm albumin-bound paclitaxel 24Leucovorin 18Capecitabine 15Albumin-Bound Paclitaxel 15S 1 (combination) 14Taxes 12Irinotecan 11pembrolizumab 9folfirinox 9Radiosurgery 9Radiotherapy 7Drug Therapy 7Cisplatin 7irinotecan sucrosofate 6Pancreaticoduodenectomy 5Paclitaxel 5Injections 5Docetaxel 5Blood Specimen Collection 5apatinib 4Radiofrequency Ablation 4Radiation 4Biopsy 4tislelizumab 3rubitecan 3nimotuzumab 3camrelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Pancreatic Neoplasms × donafenib × Clear all
NCT05138159 2021-11-30

A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

Fudan University

Phase 2 Unknown
10 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡